SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
---|---|---|---|---|---|---|---|---|---|
26-May-22 5:28 PM View: | Gueth Anton Director | Antares Pharma Inc. (ATRS) | 24-May-22 | Disposition | 386,132 | $5.60 | $2,162,340.00 | (83%) 467.58K to 81.44K | |
26-May-22 5:26 PM View: | Smith Karen L. Director | Antares Pharma Inc. (ATRS) | 24-May-22 | Disposition | 79,645 | $5.60 | $446,012.00 | (100%) 79.64K to 0 | |
26-May-22 5:25 PM View: | Graham Peter J See Remarks | Antares Pharma Inc. (ATRS) | 24-May-22 | Disposition | 740,843 | $5.60 | $4,148,720.00 | (100%) 740.84K to 0 | |
26-May-22 5:24 PM View: | Powell Fred M Executive Vice President & CFO | Antares Pharma Inc. (ATRS) | 24-May-22 | Disposition | 915,270 | $5.60 | $5,125,510.00 | (100%) 915.27K to 0 | |
26-May-22 5:30 PM View: | Roche Robert P Jr Director | Antares Pharma Inc. (ATRS) | 24-May-22 | Disposition | 167,817 | $5.60 | $939,775.00 | (100%) 167.82K to 0 | |
26-May-22 5:26 PM View: | Jacob Leonard S Director | Antares Pharma Inc. (ATRS) | 24-May-22 | Disposition | 170,575 | $5.60 | $955,220.00 | (100%) 170.57K to 0 | |
26-May-22 5:28 PM View: | Gueth Anton Director | Antares Pharma Inc. (ATRS) | 24-May-22 | Disposition | 1,800 | $5.60 | $10,080.00 | (2%) 81.44K to 79.64K | |
26-May-22 5:27 PM View: | Richardson Peter C See Remarks | Antares Pharma Inc. (ATRS) | 24-May-22 | Disposition | 50,613 | $5.60 | $283,433.00 | (100%) 50.61K to 0 | |
26-May-22 5:24 PM View: | Garrity Thomas J Director | Antares Pharma Inc. (ATRS) | 24-May-22 | Disposition | 249,858 | $5.60 | $1,399,200.00 | (100%) 249.86K to 0 | |
26-May-22 5:28 PM View: | Gueth Anton Director | Antares Pharma Inc. (ATRS) | 24-May-22 | Disposition | 79,645 | $5.60 | $446,012.00 | (100%) 79.64K to 0 | |
26-May-22 5:22 PM View: | Greenleaf Peter Director | Antares Pharma Inc. (ATRS) | 24-May-22 | Disposition | 79,645 | $5.60 | $446,012.00 | (100%) 79.64K to 0 | |
26-May-22 5:23 PM View: | Apple Robert F President and CEO Director | Antares Pharma Inc. (ATRS) | 24-May-22 | Disposition | 2,862,460 | $5.60 | $16,029,800.00 | (100%) 2.86M to 0 | |
04-Mar-22 6:36 PM View: | Powell Fred M Executive Vice President & CFO | Antares Pharma Inc. (ATRS) | 03-Mar-22 | Grant | 27,780 | -- | -- | 4% 774.76K to 802.54K | |
04-Mar-22 6:38 PM View: | Apple Robert F President & CEO Director | Antares Pharma Inc. (ATRS) | 03-Mar-22 | Grant | 86,814 | -- | -- | 4% 2.44M to 2.53M | |
04-Mar-22 6:34 PM View: | Graham Peter J EVP General Counsel, Secretary | Antares Pharma Inc. (ATRS) | 03-Mar-22 | Payment of Exercise | 13,635 | $3.80 | $51,813.00 | (2%) 630.24K to 616.61K | |
04-Mar-22 6:38 PM View: | Apple Robert F President & CEO Director | Antares Pharma Inc. (ATRS) | 03-Mar-22 | Payment of Exercise | 37,695 | $3.80 | $143,241.00 | (1%) 2.53M to 2.49M | |
04-Mar-22 6:34 PM View: | Graham Peter J EVP General Counsel, Secretary | Antares Pharma Inc. (ATRS) | 03-Mar-22 | Grant | 26,044 | -- | -- | 4% 604.2K to 630.24K | |
04-Mar-22 6:36 PM View: | Powell Fred M Executive Vice President & CFO | Antares Pharma Inc. (ATRS) | 03-Mar-22 | Payment of Exercise | 11,506 | $3.80 | $43,722.80 | (1%) 802.54K to 791.04K | |
18-Feb-22 7:19 PM View: | Graham Peter J EVP General Counsel, Secretary | Antares Pharma Inc. (ATRS) | 16-Feb-22 | Grant | 23,068 | -- | -- | 4% 594.43K to 617.5K | |
18-Feb-22 7:16 PM View: | Powell Fred M Executive Vice President & CFO | Antares Pharma Inc. (ATRS) | 16-Feb-22 | Payment of Exercise | 11,496 | $3.66 | $42,075.40 | (1%) 786.26K to 774.76K | |
18-Feb-22 7:16 PM View: | Powell Fred M Executive Vice President & CFO | Antares Pharma Inc. (ATRS) | 16-Feb-22 | Grant | 24,606 | -- | -- | 3% 761.65K to 786.26K | |
18-Feb-22 7:13 PM View: | Apple Robert F President & CEO Director | Antares Pharma Inc. (ATRS) | 16-Feb-22 | Grant | 76,893 | -- | -- | 3% 2.4M to 2.47M | |
18-Feb-22 7:19 PM View: | Graham Peter J EVP General Counsel, Secretary | Antares Pharma Inc. (ATRS) | 16-Feb-22 | Payment of Exercise | 13,299 | $3.66 | $48,674.30 | (2%) 617.5K to 604.2K | |
18-Feb-22 7:13 PM View: | Apple Robert F President & CEO Director | Antares Pharma Inc. (ATRS) | 16-Feb-22 | Payment of Exercise | 34,282 | $3.66 | $125,472.00 | (1%) 2.47M to 2.44M | |
04-Feb-22 10:00 PM View: | Jacob Leonard S Director | Antares Pharma Inc. (ATRS) | 26-Oct-21 | Gift | 125,000 | -- | -- | (42%) 295.57K to 170.57K | |
31-Aug-21 6:26 PM View: | Jacob Leonard S Director | Antares Pharma Inc. (ATRS) | 27-Aug-21 | Grant | 24,679 | $2.24 | $55,281.00 | 9% 284.72K to 309.39K | |
31-Aug-21 6:26 PM View: | Jacob Leonard S Director | Antares Pharma Inc. (ATRS) | 27-Aug-21 | Payment of Exercise | 13,820 | $4.00 | $55,280.00 | (4%) 309.39K to 295.57K | |
09-Jul-21 5:08 PM View: | Gueth Anton Director | Antares Pharma Inc. (ATRS) | 08-Jul-21 | Market Sale (Planned) | 100,000 | $4.29 | $429,000.00 | (18%) 567.58K to 467.58K | (< 1%) |
14-Jun-21 6:24 PM View: | Powell Fred M Executive Vice President & CFO | Antares Pharma Inc. (ATRS) | 13-Jun-21 | Payment of Exercise | 29,207 | $4.45 | $129,971.00 | (4%) 790.86K to 761.65K | (< 1%) |
14-Jun-21 6:21 PM View: | Graham Peter J EVP General Counsel, Secretary | Antares Pharma Inc. (ATRS) | 13-Jun-21 | Payment of Exercise | 14,790 | $4.45 | $65,815.50 | (2%) 609.22K to 594.43K | (< 1%) |
14-Jun-21 6:20 PM View: | Apple Robert F President & CEO Director | Antares Pharma Inc. (ATRS) | 13-Jun-21 | Payment of Exercise | 40,892 | $4.45 | $181,969.00 | (2%) 2.44M to 2.4M | (< 1%) |
14-Jun-21 6:21 PM View: | Graham Peter J EVP General Counsel, Secretary | Antares Pharma Inc. (ATRS) | 11-Jun-21 | Payment of Exercise | 23,010 | $4.45 | $102,394.00 | (4%) 632.23K to 609.22K | (< 1%) |
14-Jun-21 6:20 PM View: | Apple Robert F President & CEO Director | Antares Pharma Inc. (ATRS) | 11-Jun-21 | Payment of Exercise | 58,317 | $4.45 | $259,511.00 | (2%) 2.5M to 2.44M | (< 1%) |
14-Jun-21 6:25 PM View: | Roche Robert P Jr Director | Antares Pharma Inc. (ATRS) | 10-Jun-21 | Grant | 25,452 | $4.42 | $112,498.00 | 18% 142.37K to 167.82K | < 1% |
14-Jun-21 6:24 PM View: | Powell Fred M Executive Vice President & CFO | Antares Pharma Inc. (ATRS) | 10-Jun-21 | Grant | 85,973 | $4.42 | $380,001.00 | 12% 704.89K to 790.86K | < 1% |
14-Jun-21 6:20 PM View: | Apple Robert F President & CEO Director | Antares Pharma Inc. (ATRS) | 10-Jun-21 | Grant | 248,869 | $4.42 | $1,100,000.00 | 11% 2.25M to 2.5M | < 1% |
14-Jun-21 6:21 PM View: | Garrity Thomas J Director | Antares Pharma Inc. (ATRS) | 10-Jun-21 | Grant | 25,452 | $4.42 | $112,498.00 | 11% 224.41K to 249.86K | < 1% |
14-Jun-21 6:22 PM View: | Greenleaf Peter Director | Antares Pharma Inc. (ATRS) | 10-Jun-21 | Grant | 25,452 | $4.42 | $112,498.00 | 47% 54.19K to 79.64K | < 1% |
14-Jun-21 6:25 PM View: | Richardson Peter C EVP, R&D Chief Medical Officer | Antares Pharma Inc. (ATRS) | 10-Jun-21 | Grant | 36,199 | $4.42 | $160,000.00 | 100% 0 to 36.2K | < 1% |
14-Jun-21 6:21 PM View: | Graham Peter J EVP General Counsel, Secretary | Antares Pharma Inc. (ATRS) | 10-Jun-21 | Grant | 85,973 | $4.42 | $380,001.00 | 16% 546.26K to 632.23K | < 1% |
14-Jun-21 6:24 PM View: | Jacob Leonard S Director | Antares Pharma Inc. (ATRS) | 10-Jun-21 | Grant | 31,674 | $4.42 | $139,999.00 | 13% 253.04K to 284.72K | < 1% |
14-Jun-21 6:23 PM View: | Gueth Anton Director | Antares Pharma Inc. (ATRS) | 10-Jun-21 | Grant | 25,452 | $4.42 | $112,498.00 | 5% 542.13K to 567.58K | < 1% |
14-Jun-21 6:27 PM View: | Smith Karen L. Director | Antares Pharma Inc. (ATRS) | 10-Jun-21 | Grant | 25,452 | $4.42 | $112,498.00 | 47% 54.19K to 79.64K | < 1% |
10-Jun-21 5:39 PM View: | Powell Fred M Executive Vice President & CFO | Antares Pharma Inc. (ATRS) | 08-Jun-21 | Payment of Exercise | 12,045 | $4.39 | $52,877.50 | (2%) 716.93K to 704.89K | (< 1%) |
10-Jun-21 5:38 PM View: | Graham Peter J EVP General Counsel, Secretary | Antares Pharma Inc. (ATRS) | 08-Jun-21 | Payment of Exercise | 15,996 | $4.39 | $70,222.40 | (3%) 562.25K to 546.26K | (< 1%) |
10-Jun-21 5:37 PM View: | Apple Robert F President & CEO Director | Antares Pharma Inc. (ATRS) | 08-Jun-21 | Payment of Exercise | 44,223 | $4.39 | $194,139.00 | (2%) 2.29M to 2.25M | (< 1%) |
06-May-21 4:53 PM View: | Gueth Anton Director | Antares Pharma Inc. (ATRS) | 04-May-21 | Option Exercise | 40,000 | $1.66 | $66,400.00 | 8% 502.13K to 542.13K | |
03-May-21 5:56 PM View: | Gueth Anton Director | Antares Pharma Inc. (ATRS) | 29-Apr-21 | Option Exercise | 72,669 | $1.66 | $120,631.00 | 17% 429.46K to 502.13K | |
12-Mar-21 7:04 PM View: | Garrity Thomas J Director | Antares Pharma Inc. (ATRS) | 11-Mar-21 | Market Option Sale (Planned) | 50,000 | $4.28 | $214,000.00 | (18%) 274.41K to 224.41K | 11% |
12-Mar-21 7:04 PM View: | Garrity Thomas J Director | Antares Pharma Inc. (ATRS) | 11-Mar-21 | Option Exercise | 50,000 | $1.12 | $56,000.00 | 22% 224.41K to 274.41K |